TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02727569

Intervention type: DEVICE
Intervention: New visual field algorithm with DLS
Description: Mathematical model (software based) to derive retinal sensitivity.

Intervention type: DEVICE
Intervention: New visual field algorithm with DLS
Description: Mathematical model (software based) to derive retinal sensitivity.

Intervention type: DEVICE
Intervention: SITA algorithm
Description: Mathematical model (software based) to derive retinal sensitivity. Commercially available.

Intervention type: DEVICE
Intervention: New visual field algorithm with MMDT
Description: Mathematical model (software based) to derive retinal sensitivity.
Study: NCT03238963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1467335
Description: Once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily
Study: NCT03862014

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SDF+KI
Description: Molar with MIH will be treated with SDF+KI

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SDF+KI+GIC(SMART)
Description: Molar with MIH will be treated with SDF+KI+GIC(SMART)
Study: NCT02592915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine hydrochloride
Description: Single bolus of clonidine hydrochloride 0.3µg/kg (max 150 µg/kg) administered IV after induction and obtaining a stable anaesthetic level

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Single bolus of physiologic sodium chloride serum administered IV after induction and obtaining a stable anaesthetic level
Study: NCT00245960

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etanercept

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etanercept

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT03197766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 111
Description: Subcutaneous injection of 15 μg/kg of BMN 111 daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection of 15 μg/kg of placebo daily
Study: NCT00614562

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurally adjusted ventilatory assist (NAVA)
Description: NAVA for 72 hours
Study: NCT02170545

Intervention type: OTHER
Intervention: Dual Energy Computed Tomography
Description: A Dual Energy Computed Tomography scan will be performed on both upper arms.
Study: NCT01836172

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: YJP-14
Description: An 50% ethanolic extract of Lindera obtusiloba stems

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: YJP-14
Description: An 50% ethanolic extract of Lindera obtusiloba stems

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: YJP-14
Description: An 50% ethanolic extract of Lindera obtusiloba stems
Study: NCT02784288

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Videofluoroscopy
Description: All patients undergo a videofluoroscopy procedure one year after completion of therapy to assess swallowing function.
Study: NCT02734862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD101
Description: Intravenous antifungal therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD101
Description: Intravenous antifungal therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caspofungin
Description: Intravenous antifungal therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: oral antifungal therapy
Study: NCT01836172

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: YJP-14
Description: An 50% ethanolic extract of Lindera obtusiloba stems
Study: NCT04554537

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART
Description: A treatment program developed to address specific brain functions found to be crucial for the recovery following brain injury.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Brain Health Workshop
Description: A psychoeducation program designed to provide in depth information to participants about the neuroscience behind their TBI and PTSD and the symptoms and challenges they may experience.
Study: NCT01609777

Intervention type: PROCEDURE
Group type: OTHER
Intervention: SBAR
Description: situation, background, assessment, recommendation
Study: NCT01044927

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Care
Description: Comparison of the effect of COPD education, self-management instruction, home monitoring with a Health Buddy Telemonitor, pulse oximeter, pedometer and spirometer, and enhanced communication with a study coordinator (cell phone access)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy
Description: No intervention was made. Data measurements were taken at 0, 3, 6 and 9 months, as in the active intervention group.
Study: NCT05375097

Intervention type: OTHER
Intervention: Erenumab
Description: Patients who met the responder definition of two or more erenumab prescriptions with no evidence of switch to other CGRPi were included in the main analyses
Study: NCT03697694

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 500mg of Aronox® >40% polyphenol aronia extract
Description: Name: Aronia PE 40% polyphenols Description: Powdered extract obtained from aronia berries (Aronia melanocarpa) Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg aronia extract Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX / Virage sante

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Name: Placebo Description: Identical formulation as the treatment consisting of colored maltodextrin using artificial colors Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg placebo Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX (Advance nutraceutical) / Virage sante
Study: NCT02387697

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards Sapien XT Valve
Description: The device will be implanted in the present study to prevent abdominal venous congestion and to improve the function of the tricuspid valve which is located in the low pressure system in the right heart.
Study: NCT00558792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isovue 370, 70 mL
Description: 70 mL of iopamidol injection 370 injected at a rate of \>=4 mL/second

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isovue 370, 80 mL
Description: 80 mL of iopamidol injection 370 injected at a rate of \>=4 mL/second

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isovue 370, 90 mL
Description: 90 mL of iopamidol injection 370 injected at a rate of \>=4 mL/second
Study: NCT02314689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) citrulline
Study: NCT02734862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous placebo
Description: normal saline
Study: NCT00388804

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Radiation treatment given over about 8 1/2 weeks; 42 treatments, 5 days per week with 2 days rest in between.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Radiation treatment given over about 8 1/2 weeks; 42 treatments, 5 days per week with 2 days rest in between.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide
Description: 50 mg By Mouth (PO) Daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide
Description: 22.5 mg Intramuscularly (IM) Every 3 Months or 7.5 mg IM Every 1 Month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin
Description: 10.8 mg Subcutaneously Every 3 Months or 3.6 mg Subcutaneously Every 1 Month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flutamide
Description: 250 mg by mouth three times daily on first 21-30 Days. May be used instead of Bicalutamide.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: Questionnaires regarding health-related quality of life given before therapy begins, each taking about 15 minutes to complete.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: Questionnaires regarding health-related quality of life given before therapy begins, each taking about 15 minutes to complete.
Study: NCT04165044

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Leukocyte and Platelet Rich Fibrin plus Coronally Advanced Flap
Description: The Coronally advanced flap was made following the protocol described by Zucchelli et al. in 2007. (39). When the margin of the flap was able to passively extend until more coronal of the CEJ the coronal mobilization of the flap was considered satisfactory. A double L-PRF membrane was positioned at the level of CEJ, getting the stabilization with 5-0 resorbable suture. After that, the flap was coronally advanced and stabilized with interrupted sutures (5-0 resorbable) anchored to incisal contact points (mesial and distal) created with a flowable, light-curing resin material in the treated tooth. Finally, gentle pressure over the area with a moistened gauze with saline solution was performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Connective tissue graft plus Coronally Advanced Flap
Description: The Coronally advanced flap was made following the protocol described by Zucchelli et al. in 2007. (39). When the margin of the flap was able to passively extend until more coronal of the CEJ the coronal mobilization of the flap was considered satisfactory. Then connective tissue graft obtained from the palate was positioned at the level of CEJ, getting the stabilization with 5-0 resorbable suture. After that, the flap was coronally advanced and stabilized with interrupted sutures (5-0 resorbable) anchored to incisal contact points (mesial and distal) created with a flowable, light-curing resin material in the treated tooth. Finally, gentle pressure over the area with a moistened gauze with saline solution was performed.
Study: NCT03223051

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor assessment
Description: An occupational therapist install the patient sitting in front of the test board and tell him the instructions
Study: NCT04243512

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted eating
Description: Restrict food and beverage intake (except water) to a 10-hour window
Study: NCT00092092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast chewable tablets
Description: Montelukast sodium 5 mg chewable tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast chewable tablets
Description: Montelukast sodium 5 mg chewable tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide inhaler
Description: Budesonide 200 mcg inhalation powder

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide inhaler
Description: Budesonide 200 mcg inhalation powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to montelukast chewable tablets
Description: Placebo chewable tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to montelukast chewable tablets
Description: Placebo chewable tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to budesonide inhaler
Description: Placebo inhalation powder

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to budesonide inhaler
Description: Placebo inhalation powder
Study: NCT00994175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT01894997

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AV Impulse System Model 6000
Study: NCT02760147

Intervention type: DEVICE
Group type: OTHER
Intervention: Pressure Support Over Support
Description: Pressure Support Level upward by 50%, 2 hours

Intervention type: DEVICE
Group type: OTHER
Intervention: Pressure Support Over Support
Description: Pressure Support Level upward by 50%, 2 hours

Intervention type: DEVICE
Group type: OTHER
Intervention: Pressure Support Under Support
Description: Pressure Support Level downward by 50%, 2 hours

Intervention type: DEVICE
Group type: OTHER
Intervention: Pressure Support Under Support
Description: Pressure Support Level downward by 50%, 2 hours

Intervention type: DEVICE
Group type: OTHER
Intervention: PEEP Over Level
Description: PEEP Level upward by 50%, 2 hours

Intervention type: DEVICE
Group type: OTHER
Intervention: PEEP Over Level
Description: PEEP Level upward by 50%, 2 hours

Intervention type: DEVICE
Group type: OTHER
Intervention: PEEP Under Level
Description: PEEP Level downward by 50%, 2 hours

Intervention type: DEVICE
Group type: OTHER
Intervention: PEEP Under Level
Description: PEEP Level downward by 50%, 2 hours
Study: NCT01395069

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nepafenac 0.1%
Description: 1 drop QID for 1 month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac 0.5%
Description: 1 drop QID for 1 month

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (sterile saline drops)
Description: 1 drop QID for 1 month
Study: NCT03380195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Watermelon juice
Description: Subject drinks 355ml of watermelon juice 1 hour prior to submaximal exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sport drink
Description: Subject drinks 355ml of Gatorade 1 hour prior to submaximal exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sugar water
Description: Subject drinks 355ml of sugar water (22.5g) 1 hour prior to submaximal exercise

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Subject drinks 355ml of water 1 hour prior to submaximal exercise
Study: NCT01833208

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo single-fraction radiation therapy
Study: NCT02444780

Intervention type: PROCEDURE
Intervention: no intervention, blood is sampled for routine
Description: no intervention, blood sampled for standard evaluation will be used for determination of plasma glutamin
Study: NCT04949802

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ViaLase Laser
Description: ViaLase Laser System to create an aperture through the trabecular meshwork for the reduction of IOP in subjects with primary open-angle glaucoma
Study: NCT02177253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide / Salbutamol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Inhalation solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COMBIVENT Inhalation Aerosol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Inhalation Aerosol
Study: NCT03427697

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality and accommodation relax techniques in combination
Description: The children will be given head-mounted video display to watch video at break of classes, 40 minutes per day in total. The video will be shown by virtual reality and accommodation relax techniques in combination.
Study: NCT02734862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous placebo
Description: normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous placebo
Description: normal saline
Study: NCT01932762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: 100 mg every day (QD) orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: 100 mg every day (QD) orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: 100 mg every day (QD) orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: 100 mg every day (QD) orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: 50 mg QD orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: 50 mg QD orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: 50 mg QD orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Administered twice daily (BID) orally at a total daily dose of 800 mg to 1400 mg based on participant's weight on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Administered twice daily (BID) orally at a total daily dose of 800 mg to 1400 mg based on participant's weight on Day 1
Study: NCT02734862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral placebo
Description: microcrystalline cellulose
Study: NCT01932762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Administered twice daily (BID) orally at a total daily dose of 800 mg to 1400 mg based on participant's weight on Day 1
Study: NCT01511497

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04427429
Description: Intravenous, single dose given over 1 hour with experimental dose. Subjects can receive one of four potential doses - 300, 1000, 1500 or 2000 mg.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Intravenous, normal saline
Study: NCT00497874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-tailored intervention
Description: Stage-based manual and three computer-tailored reports
Study: NCT04445298

Intervention type: DIAGNOSTIC_TEST
Intervention: Transepidermal water loss
Description: We will assess the skin with transepidermal water loss (TEWL) by using a condenser-chamber system placed lightly on the skin. This will be performed at baseline, then after every 4 skin tape strips.

Intervention type: DIAGNOSTIC_TEST
Intervention: Transepidermal water loss
Description: We will assess the skin with transepidermal water loss (TEWL) by using a condenser-chamber system placed lightly on the skin. This will be performed at baseline, then after every 4 skin tape strips.
Study: NCT03917277

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Musculoskeletal ultrasound
Description: Ankle sonographic examination will be performed using Samsung UGEO H60 ultrasound machine in use since 2016. In order to optimize reproducibility, all examinations will be performed by a single examiner. Multiplanar (longitudinal/transverse) scanning will be done in B- and PD-mode to identify pathologies defined by the OMERACT network in the following structures:~1. Talocrural joint:synovial fluid (scored 0-3);synovitis with synovial hypertrophy and PD signal (each scored 0-3); bone erosion with distance between cortices and presence/absence of DP signal~2. Tibialis anterior,tibialis posterior, extensor digitorum longus, fibularis brevis,fibularis tertius,and calcaneal tendons: presence/absence of tenosynovitis, thickening, hypoechogenicity, nodularity, fusiform aspect, and DP signal~3. Calcaneal enthesis: presence/absence of thickening,hypoechogenicity,calcification, cortical irregularity,and DP signal~4. Retrocalcaneal and calcaneal bursa: presence/absence of bursitis and DP signal
Study: NCT00560703

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COL-101 (doxycycline, USP) capsules
Description: 40mg, once per day for 84 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: sugar capsule
Study: NCT01315522

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ComVi stent
Description: Endoscopic insertion of ComVi stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Uncovered SEMS
Description: Endoscopic insertion of uncovered SEMS
Study: NCT02779075

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Subjects will be studied on 2 occasions, in random order. During the saline study they will be infused with saline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exendin-9,39
Description: Subjects will be studied on 2 occasions, in random order. During the Exendin-9,39 study day they will be infused with Exendin-9,39. Exendin-9,39 blocks the actions of specific hormones called incretins, that are produced in the gut in health and in larger quantities after gastric bypass surgery.
Study: NCT01104987

Intervention type: DRUG
Intervention: alendronate
Description: One tablet of alendronate à 70 mg once a week during two years.
Study: NCT01765816

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high intensity interval training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: high intensity interval training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: moderate intensity training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: moderate intensity training
Study: NCT03374488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered intravenously Day 1 of each cycle every 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab administered intravenously Day 1 of each cycle every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Epacadostat administered orally twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered orally twice daily.
Study: NCT04659057

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized Lidocaine
Description: will receive nebulized lidocaine 2%, 1 mg/kg with a maximum dose of 100 mg (5 ml).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized dexmedetomidine
Description: will receive nebulized dexmedetomidine (1 μg/kg diluted in 5 ml of saline 0.9%).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized lidocaine and dexmedetomidine
Description: will receive nebulized lidocaine 2% (0.5 mg/kg) and dexmedetomidine 0.5 μg/kg dexmedetomidine in 5 ml of saline 0.9%.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: will receive nebulized saline 0.9% (5 ml) as control group.
Study: NCT02333500

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: olfactory workshop
Description: olfactory workshop

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: other workshop
Description: other workshop: discussion group, dance and body Expression

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: control group